Because these tumors are so rare, there have been no randomized clinical trials yet conducted with respect to specific treatment regimens for any subtype. Very few histospecific studies of individual subtypes SCL have been published in the literature; most data has been small retrospective case series or case reports. In many cases, SCL are generally treated like other NSCLC. However, as SCL are considered particularly aggressive non-small cell lung cancers, some experts recommend particularly aggressive treatment approach to these tumors. Little is known about the effects of EGFR inhibitors in SC, although some evidence suggests that these tumors are not likely to be highly responsive.
Sarcomatoid carcinoma of the lung
Epithelial-myoepithelial carcinoma of the lung
Giant-cell carcinoma of the lung
Pulmonary sclerosing pneumocytoma
Mucinous cystadenocarcinoma of the lung
Adenocarcinoma of the lung
Salivary gland–like carcinoma of the lung
Adenosquamous lung carcinoma